Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,463.00    7.00 (0.48%)
Bid:
1,468.00
Ask:
1,469.00
Spread: 1.00 (0.068%)
Market Cap: £3.10b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

10 Apr 2018 14:34

RNS Number : 4612K
Hikma Pharmaceuticals Plc
10 April 2018
 

 

Hikma Pharmaceuticals PLC - EIP Awards

LONDON, 10 April 2018: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 10 April 2015 under the 2014 Executive Incentive Plan ("EIP") which was completed on10 April 2018. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the EIP is £nil.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 19,945

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

 

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 14,165

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 13,811

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 10,089

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter SpeirsCompany Secretary, responsible for releasing this announcement+44 (0) 20 7399 2760

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBXGDSXXBBGIG
Date   Source Headline
3rd Mar 20225:44 pmRNSTransaction in Own Shares
3rd Mar 20222:44 pmRNSDirector/PDMR Shareholding
2nd Mar 20226:18 pmRNSTransaction in Own Shares
1st Mar 20225:57 pmRNSTransaction in Own Shares
28th Feb 20226:37 pmRNSTransaction in Own Shares
28th Feb 20225:16 pmRNSDirector/PDMR Shareholding
25th Feb 20225:58 pmRNSHikma Share Buyback Programme
25th Feb 20229:37 amRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSShare Buyback Programme
24th Feb 20227:00 amRNSDirectorate Change
24th Feb 20227:00 amRNSFinal Results
23rd Feb 20229:23 amRNSHolding(s) in Company
16th Feb 202211:26 amRNSDirector/PDMR Shareholding
11th Feb 202210:17 amRNSHolding(s) in Company
8th Feb 202210:17 amRNSNotice of Results
3rd Feb 20227:00 amRNSHikma completes acquisition of Teligent
2nd Feb 202210:04 amRNSTotal Voting Rights
24th Jan 202212:45 pmRNSHolding(s) in Company
17th Jan 20227:00 amRNSAcquisition
12th Jan 20223:22 pmRNSHolding(s) in Company
10th Jan 20227:00 amRNSHikma Launches 503B Sterile Compounding Business
4th Jan 20222:55 pmRNSTotal Voting Rights
16th Dec 20211:42 pmRNSHolding(s) in Company
14th Dec 20212:34 pmRNSHolding(s) in Company
9th Dec 20217:00 amRNSRichter and Hikma sign agreement for denosumab
2nd Dec 202110:33 amRNSHolding(s) in Company
23rd Nov 20219:57 amRNSHolding(s) in Company
17th Nov 202110:35 amRNSHolding(s) in Company
4th Nov 20217:00 amRNSTrading Statement
1st Nov 20212:06 pmRNSTotal Voting Rights
4th Oct 20219:55 amRNSBlock listing Interim Review
27th Sep 20217:00 amRNSHikma acquires Custopharm
23rd Sep 20217:30 amRNSAdditional Listing
27th Aug 202112:15 pmRNSBio-Thera and Hikma announce exclusive agreement
6th Aug 20217:00 amRNSHalf-year Report
2nd Aug 20212:48 pmRNSTotal Voting Rights
19th Jul 20219:27 amRNSNotice of Results
5th Jul 20213:43 pmRNSTotal Voting Rights
2nd Jun 20211:14 pmRNSTotal Voting Rights
17th May 20214:00 pmRNSDirector/PDMR Shareholding
30th Apr 20217:00 amRNSHikma announces US FDA approval of KLOXXADO
30th Apr 20217:00 amRNSTrading Statement
26th Apr 202111:19 amRNSHolding(s) in Company
23rd Apr 20213:51 pmRNSResult of AGM
21st Apr 20217:00 amRNSHikma resumes launch of generic Advair Diskus®
13th Apr 202111:35 amRNSBlock listing Interim Review
13th Apr 20219:19 amRNSTotal Voting Rights
17th Mar 20212:29 pmRNSDirector/PDMR Shareholding
17th Mar 202111:08 amRNSAnnual Financial Report
15th Mar 202111:24 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.